naa a22 4500 510779751 CHVBK 20180411083243.0 cr unu---uuuuu 180411e20130801xx s 000 0 eng 10.1007/s11892-013-0391-y doi (NATIONALLICENCE)springer-10.1007/s11892-013-0391-y Stanton Robert Joslin Diabetes Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA aut Combination Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Diabetic Kidney Disease [Elektronische Daten] [Robert Stanton] Angiotensin converting enzyme inhibitors (ACE-I) and angiotensin receptor blockers (ARB) have played a major role in slowing the progression of diabetic kidney disease, since they lower urine protein levels, lower blood pressure, and slow progression. Studies have suggested that the combination of ACE-I and ARB offered greater benefits for patients with diabetic kidney disease. In 2008, the large ONTARGET study reported no benefit with combination therapy, as compared with monotherapy. This study has changed practice patterns, but few patients in this study had diabetic kidney disease. In this review, the data in favor of the combination use of these agents in patients with diabetic kidney disease and data against the combination are reviewed. At this time, there is little support for using the combination in diabetic patients with no kidney disease or early stage diabetic kidney disease. But there are patients who may benefit from combination use. Springer Science+Business Media New York, 2013 Diabetic kidney disease nationallicence ACE inhibitors nationallicence Angiotensin receptor blockers nationallicence Current Diabetes Reports Springer US; http://www.springer-ny.com 13/4(2013-08-01), 567-573 1534-4827 13:4<567 2013 13 11892 https://doi.org/10.1007/s11892-013-0391-y text/html Onlinezugriff via DOI 1 review-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s11892-013-0391-y text/html Onlinezugriff via DOI NATIONALLICENCE 100 1- Stanton Robert Joslin Diabetes Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA aut NATIONALLICENCE 773 0- Current Diabetes Reports Springer US; http://www.springer-ny.com 13/4(2013-08-01), 567-573 1534-4827 13:4<567 2013 13 11892 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer